The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
The endocannabinoid system in obesity and type 2 diabetes
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Abdominal obesity and metabolic syndrome
Després, J.-P., & Lemieux, I. (2006) · Nature · doi:10.1038/nature05488 · Cited by 4,354
The molecular logic of endocannabinoid signalling
Piomelli, D. (2003) · Nature Reviews Neuroscience · doi:10.1038/nrn1247 · Cited by 1,957
Leptin-regulated endocannabinoids are involved in maintaining food intake
Di Marzo, V., Goparaju, S. K., Wang, L., Liu, J., Bátkai, S., Járai, Z., Fezza, F., Miura, G. I., Palmiter, R. D., Sugiura, T., et al. (2001) · Nature · doi:10.1038/35071088 · Cited by 1,559
Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia
Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · cited 1×
“The RIO-Lipids trial specifically examined the effects of rimonabant on metabolic risk factors, including adiponectin levels [72].”
BackgroundEfficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials
Christensen, R., Kristensen, P. K., Bartels, E. M., Bliddal, H., & Astrup, A. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61721-8 · Cited by 1,097 · cited 1×
“The data have been subject to different interpretations [78, 80], but clearly point to depressive disorders, nausea, anxiety and dizziness as the most frequent side effects leading to discontinuation.”
BackgroundActivation of the peripheral endocannabinoid system in human obesity
Engeli, S., Böhnke, J., Feldpausch, M., Gorzelniak, K., Janke, J., Bátkai, S., Pacher, P., Harvey-White, J., Luft, F. C., Sharma, A. M., et al. (2005) · Diabetes · doi:10.2337/diabetes.54.10.2838 · Cited by 686 · cited 4×
“Evidence in humans The first evidence of peripheral elevation of EC tone in humans came from studies in overweight/obese women with a binge eating disorder [51] and in obese postmenopausal women [52], in whom elevated blood levels of anandamide only, or both anandamide and 2-AG, respectively, were reported.”
BackgroundInfluentialRademacher, D. J., Meier, S. E., Shi, L., Vanessa Ho, W.-S., Jarrahian, A., & Hillard, C. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.06.012 · Cited by 233
Murdolo, G., Kempf, K., Hammarstedt, A., Herder, C., Smith, U., & Jansson, P. A. (2007) · Journal of Endocrinological Investigation · doi:10.1007/bf03347440 · Cited by 58
Cited by
Pathophysiology of human visceral obesity: an update
Tchernof, A., & Després, J.-P. (2013) · Physiological Reviews · doi:10.1152/physrev.00033.2011 · Cited by 2,583
Marine omega-3 fatty acids and inflammatory processes: effects, mechanisms and clinical relevance
Calder, P. C. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2014.08.010 · Cited by 1,717
Omega‐3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology?
Calder, P. C. (2013) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2012.04374.x · Cited by 1,347
β‐caryophyllene and β‐caryophyllene oxide—natural compounds of anticancer and analgesic properties
Fidyt, K., Fiedorowicz, A., Strządała, L., & Szumny, A. (2016) · Cancer Medicine · doi:10.1002/cam4.816 · Cited by 674
The Endocannabinoid System in Energy Homeostasis and the Etiopathology of Metabolic Disorders
Silvestri, C., & Di Marzo, V. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.03.001 · Cited by 543
Self-citation
Metadata
- Authors
- Di Marzo, V.
- Venue
- Diabetologia
- Published
- 2008-06-18
- Volume
- 51
- Issue
- 8
- Pages
- 1356-1367
- ISSN
- 0012-186X (ISSN-L)
- 1432-0428
- OpenAlex
- W2136608474
- Cited by
- 281
- References
- 8
- FWCI
- 19.86
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The endocannabinoid system in obesity and type 2 diabetes. https://app.cochat.ai/papers/10.1007/s00125-008-1048-2
- The paper
- Di Marzo, V. (2008). The endocannabinoid system in obesity and type 2 diabetes. Diabetologia. https://doi.org/10.1007/s00125-008-1048-2
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.